Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease
about
Alzheimer's Disease: Exploring the Role of Inflammation and Implications for TreatmentRole of pro-inflammatory cytokines released from microglia in Alzheimer's diseaseExploring Biomarkers for Alzheimer's DiseaseAPOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspectiveDisrupted sleep without sleep curtailment induces sleepiness and cognitive dysfunction via the tumor necrosis factor-α pathwayGlial contributions to neurodegeneration in tauopathies.Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidenceImplications of gliotransmission for the pharmacotherapy of CNS disorders.Linking cardiometabolic disorders to sporadic Alzheimer's disease: a perspective on potential mechanisms and mediators.TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosisMethemoglobin is an endogenous toll-like receptor 4 ligand-relevance to subarachnoid hemorrhage.Combining select neuropsychological assessment with blood-based biomarkers to detect mild Alzheimer's disease: a molecular neuropsychology approach.Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's diseaseGenotype-phenotype interactions in pediatric obstructive sleep apneaPerispinal etanercept: a new therapeutic paradigm in neurology.The potential role of proinflammatory and antiinflammatory cytokines in Alzheimer disease pathogenesis.Astrocyte signaling and neurodegeneration: new insights into CNS disorders.Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?Vaccination against Alzheimer disease: an update on future strategies.The common inflammatory etiology of depression and cognitive impairment: a therapeutic target.Systematic review of the association between Alzheimer's disease and chronic glaucoma.How strong is the relationship between glaucoma, the retinal nerve fibre layer, and neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis?Genetic Deletion of Tumor Necrosis Factor-α Attenuates Amyloid-β Production and Decreases Amyloid Plaque Formation and Glial Response in the 5XFAD Model of Alzheimer's Disease.Perispinal Delivery of CNS Drugs.Cytokines and Cytokine Receptors Involved in the Pathogenesis of Alzheimer's Disease.The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer's Disease.Immediate neurological recovery following perispinal etanercept years after brain injury.Saturated fatty acids activate microglia via Toll-like receptor 4/NF-κB signalling.Brain abscesses complicating acute pneumococcal meningitis during etanercept therapy.Suppressed microglial E prostanoid receptor 1 signaling selectively reduces tumor necrosis factor alpha and interleukin 6 secretion from toll-like receptor 3 activation.The majority of infiltrating CD8 T lymphocytes in multiple sclerosis lesions is insensitive to enhanced PD-L1 levels on CNS cells.Cross-talk between neurons and astrocytes in response to bilirubin: early beneficial effects.Mannose-binding lectin binds to amyloid β protein and modulates inflammation.Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept.Prevention of the β-amyloid peptide-induced inflammatory process by inhibition of double-stranded RNA-dependent protein kinase in primary murine mixed co-cultures.Authors' reply to Whitlock: Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence.Author's reply to Page: "Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept".Action of anti-TNF-α drugs on the progression of Alzheimer's disease: A case report.Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases.Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity.
P2860
Q26776157-3CFF0AE5-11C8-4A8D-83F5-E4172CC5B7B5Q26799870-58CAAFA3-8747-4502-993D-FFEADBB7213FQ28079218-B26AA84E-5770-44A7-936E-167060EF0708Q28085213-EE77D0F1-E560-4C8A-94D8-891C35C89F51Q28387166-52DD1F85-6733-4E0C-9A22-4AF88527E919Q32173558-5FF050C1-1A8A-4635-B44D-41D8832B4263Q33947639-71D6E4E3-5119-4DED-9CE7-EE8CA806E050Q33971765-0E3B880E-DA00-4613-9166-94EAB4E398C6Q34268223-C753CA57-A5D6-4417-8B22-2525D2B7EF1CQ35005977-7086EB26-267B-442A-94B1-5D45B5F5EC11Q35380756-1018E484-4001-4D97-BDC9-898702CEEB0AQ35559746-6CAC90D6-9094-415F-B6F8-DEF1CE4CD6ABQ36118204-28888F64-D558-4D18-839B-12DB5A165DBCQ37117125-32F0255A-A6DA-4637-8A3F-89A4D84267D7Q37762260-E3CD22D7-792B-4494-8001-57B83DE6B97DQ38042681-42FAE9DA-73B3-4E92-8A63-66F33C399FDCQ38055136-751E58CE-2888-4010-9D0B-20EE5724A192Q38103856-64B4BFE2-3545-4C18-B319-B14604354878Q38188866-BDE7A074-3D45-487F-8B93-E28269BAC716Q38245307-19E86EBA-8C8B-484C-AD8E-7260C5A429E9Q38262496-87E7C552-CF8F-463D-A91A-90BF3D2A4C6BQ38580403-84B73D22-F51A-4E0D-91C1-04110FA5EAD1Q38616054-1A07D5A1-08B0-47B9-B375-9390A64FA9EDQ38819013-F02007E2-051C-44DB-BF8B-09DD9F56A1B1Q39023028-452BED11-7870-4BB2-935C-3B01EA8FCD2CQ39182975-43DDCB40-D297-41F7-B1CF-65DE213E95C2Q39209875-D4565A7D-5C0A-49AD-BF9A-199BC250DE01Q39511870-6BE7D687-6353-41C6-928B-9B23A5108B16Q41279114-9934921D-04DB-4506-8D9C-B7485522454FQ42116332-A06F1A54-9E6A-478F-B369-EC54E7834C29Q42484597-94B1687B-FD03-47A9-AA3A-E50008954DE4Q42518637-014D2C5C-3E34-434A-AF55-5A73037E93CAQ42552479-607BEFBE-E327-478B-86A2-09F18CA8A33BQ42674268-DC575685-C0E1-4689-90ED-4FB0923C105AQ42789591-726FDC52-1830-49CC-ADE1-01ABE59C44ADQ43041358-E6BBBF2B-53AE-48EA-ADA3-D2005625D079Q43966751-3B8DC687-1521-4AB2-BD44-928826384E14Q46033935-27597AC8-09E5-4BD0-BBFD-AD47AA52CA4BQ46473889-2F39D5DC-6DF7-44B6-924D-A5014DD4F067Q47128001-E5EB0D41-4923-403E-A87E-BF1E4FF89BB3
P2860
Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease
@ast
Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease
@en
Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease
@en-gb
Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease
@nl
type
label
Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease
@ast
Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease
@en
Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease
@en-gb
Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease
@nl
altLabel
Tumour necrosis factor modulat ...... rationale and current evidence
@en
prefLabel
Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease
@ast
Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease
@en
Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease
@en-gb
Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease
@nl
P2860
P3181
P1433
P1476
Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease
@en
P2093
Edward Tobinick
P2860
P304
P3181
P356
10.2165/11310810-000000000-00000
P407
P577
2009-09-01T00:00:00Z
P5875
P6179
1033789430